At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Ripretinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
In Brief
A Phase 1 clinical trial evaluating Ripretinib and Repaglinide for GIST - Gastrointestinal Stromal Tumor. Completed, enrolled 13 participants across 3 sites.
Detailed Summary
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGIST - Gastrointestinal Stromal Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2021
Primary CompletionNov 2023
Study CompletionJul 2024
TodayJul 2026
First PostedAug 28, 2020
Enrollment StartSep 22, 2021
Primary CompletionNov 16, 2023
Study CompletionJul 29, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.8 years ago
Interventions
Ripretinibdrug
Oral KIT/PDGFRA kinase inhibitor
Repaglinidedrug
Oral antihyperglycemic agent